Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Clinical trial NCT02456701 · COMPLETED
Trial details
- NCT number
- NCT02456701
- Sponsor
- Celldex Therapeutics
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-01
- Primary completion
- 2016-10-13
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.